Podcasts about virginia school

Bob Stack is the former Managing Director of Deloitte's Washington National Tax Practice, a role he held until his recent retirement. Prior to his work for Deloitte, Bob served as the Deputy Assistant Secretary for International Tax Affairs in the Office of Tax Policy at the U.S. Department of the Treasury. In this episode of On Tax, he and Cravath partner and host Len Teti discuss how an early love of French language and international travel inspired Bob's path to tax law in front of a live audience of students, faculty and alumni at the University of Virginia School of Law. They also talk about Bob's tenure at the Treasury Department and reflect on the role senior colleagues play in building knowledge and confidence for professionals across the tax world. Hosted on Acast. See acast.com/privacy for more information.

What does it take to rebuild trust in a public health institution, and can listening be a leadership strategy? Virginia State Health Commissioner Dr. B Cameron Webb explored these questions as he stepped into his role earlier this year, beginning his tenure with a statewide listening tour. Dr. Webb shares what Virginians told him was standing between them and being healthy, how he's translating community voice into action inside a 3,200-person agency, and why trust is one of the most critical commodities in public health. He also digs into Virginia's recently released 2025–2029 Plan for Well-Being, what it means to lead through federal funding uncertainty, and how Dr. Webb is rebuilding morale inside a department that has had its own healing to do.  Dr. B. Cameron Webb is the Virginia State Health Commissioner. He previously served as a White House fellow and was a senior advisor for the White House Office of COVID-19 Response. He has advised on public health policy, access to care, and prescription drug pricing. Dr. Webb was also an assistant professor of medicine and public health science at the University of Virginia School of Medicine and in the Frank Batten School of Leadership and Public Policy.   More Links and Information  Check out more Fors Marsh MediaConnect or partner with Fors MarshExplore the Virginia Department of HealthRead up on Virginia's Plan for Well-Being 2025–2026

Professor Mitu Gulati discusses a 1970s-era unpaid debt Cambodia owes the United States and why there is no mechanism to forgive it. Gulati spoke at the Law School Foundation's Alumni Board and Council luncheon. (University of Virginia School of Law, May 8, 2026)

 Did you know Virginia treats truancy and chronic absenteeism as two different issues? Instead of jumping straight to punishment, schools focus on early communication, family meetings, and finding solutions before legal action is considered. The goal is simple: keep students engaged, remove attendance barriers, and help more kids stay on track for success. 

Lisa Doyle Howley, PhD, joins the Ripples: Physician Well-Being podcast to explore how intentional support, psychological safety and clear expectations can better prepare medical students for the transition from medical school to residency. Season 5 of "Ripples" focuses on bringing your best self to residency training while avoiding common pitfalls. ABOUT GUEST SPEAKER:  Lisa Doyle Howley, PhD is an educational psychologist and a national leader in medical education. She serves as the Senior Director for Transforming Medical Education at the Association of American Medical Colleges (AAMC), where she drives advancements in competency-based medical education (CBME) and fosters innovation in teaching and learning.  With more than three decades of experience in academic medicine, Dr. Howley has held leadership roles at institutional, regional, and national levels. She currently leads a diverse portfolio and team dedicated to transforming models of teaching and learning across the continuum of medical education. Her work accelerates the adoption of CBME, reinforces the fundamental role of the arts and humanities, advances faculty development, and ensures that new and emerging areas of medicine are effectively integrated into curricula across AAMC's member schools and teaching hospitals. Dr. Howley holds an adjunct faculty appointment at the University of North Carolina School of Medicine.  Earlier in her career, she was a member of the medical education faculty at the University of Virginia School of Medicine, where she designed and implemented performance-based assessments and simulation-enhanced curricula. She earned her bachelor's degree in psychology from the University of Central Florida and both her M.Ed. and Ph.D. in Educational Psychology from the University of Virginia. A frequent speaker and thought leader, she is dedicated to shaping the future of medical education through strategic collaboration, scholarship, and innovation.

On this Salcedo Storm Podcast:Harmeet Dhillon serves as the U.S. assistant Attorney General for the Civil Rights Division. She's a graduate of University of Virginia School of Law, using her talents to defend our people and the U.S. Constitution.

Religion can help provide answers to many questions in life -  big and small.  And in doing so, give a sense of security and understanding of the world and our place in it. But what happens when doubt starts to creep in?  As more and more people leave organized religion, is doubt the cause, or could learning how to embrace doubt actually be the answer to the modern crisis of faith? In the first of this special two part series on doubt and spirituality, we'll talk with author, poet and lecturer Christian Wiman, about what it means to have certainty that God exists, while also harboring major doubts about how to approach the divine.  And we'll talk to psychologist Julie Exline about how doubt tends to affect those who experience it, and her recommendations for constructive ways to embrace uncertainty for spiritual and personal growth.Christian Wiman is a Professor at Yale University and is an author and editor of numerous publications. His most recent books include My Bright Abyss and Glimmerings: Letters on Faith Between a Poet and a Theologian. To engage with more of his work, click here. Julie Exline,Ph.D. is the Research Director and Bonner-Lowry Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia School of Medicine.  

This Day in Legal History: Seventeenth Amendment RatifiedOn April 8, 1913, the Seventeenth Amendment to the United States Constitution became part of the Constitution after receiving the necessary number of state ratifications. This amendment fundamentally changed the method of selecting U.S. senators, shifting the power from state legislatures directly to voters. Prior to its adoption, senators were chosen by state lawmakers, a process that had increasingly drawn criticism for corruption and political deadlock. Reformers argued that legislative selection allowed special interests to exert undue influence over Senate seats. The amendment emerged during the Progressive Era, a period marked by widespread efforts to make government more democratic and transparent. By mandating direct elections, it aimed to increase accountability and restore public trust in the federal government. The change also reduced the frequency of vacancies caused by legislative gridlock in the states. Supporters viewed the amendment as a necessary correction to a system that had strayed from democratic principles. Critics, however, warned that it weakened the role of states within the federal structure. The ratification process itself reflected strong public pressure for reform across many states. Over time, the amendment reshaped the political dynamics of the Senate, making senators more responsive to public opinion. It also aligned the Senate more closely with the House of Representatives in terms of democratic legitimacy. Today, the Seventeenth Amendment remains a cornerstone of how Americans participate in federal elections, illustrating the enduring impact of Progressive Era reforms.Acting Attorney General Todd Blanche said that Donald Trump has both the right and responsibility to influence federal investigations, including those involving people Trump views as adversaries. Speaking publicly for the first time since taking the role, Blanche rejected claims that the Justice Department was improperly targeting Trump's opponents. He argued that a president is expected to guide national priorities, even when that includes investigations tied to personal or political conflicts.The Justice Department has recently pursued multiple investigations involving individuals connected to past inquiries into Trump, as well as political opponents and donors. Some of these efforts have faced resistance in court, with judges and grand juries limiting or dismissing certain cases. Blanche pointed to past prosecutions against Trump as justification, saying the president is seeking accountability for what he views as misuse of the legal system.Blanche's appointment followed Trump's firing of former Attorney General Pam Bondi, reportedly due to frustration over the pace and results of investigations. Blanche did not say whether he wants to remain in the role permanently, emphasizing that the decision rests with Trump. He also indicated he would step aside if asked, expressing loyalty to the president.Acting DOJ chief Blanche says Trump has ‘right' to influence investigations | ReutersYale Law School lost its long-held No. 1 position in the latest U.S. News & World Report law school rankings, marking the first time in 36 years it has not topped the list. Stanford Law School now holds the sole No. 1 spot, while Yale is tied for second with University of Chicago Law School. A slight drop in Yale's employment rate for graduates appears to have contributed to the shift, though other metrics like bar passage and LSAT scores remained stable.The rankings also saw broader changes among the traditionally top 14 law schools, known as the “T-14.” University of California, Berkeley School of Law and Georgetown University Law Center both fell out of that group, while Cornell Law School and Vanderbilt University Law School moved up in the rankings. Other schools, including University of Pennsylvania Carey Law School and University of Virginia School of Law, saw smaller gains, while Harvard Law School remained steady.These fluctuations reflect changes in the ranking methodology introduced in recent years after several top schools, including Yale and Berkeley, criticized the system. The updated approach relies more heavily on data reported to the American Bar Association, making small differences in employment and bar passage rates more influential.Yale loses longtime No. 1 spot on latest US law school ranking | ReutersAI startups are increasingly targeting law students as part of a broader effort to capture the legal services market. Companies like Harvey AI and Legora are offering free access and training at top law schools, hoping students will continue using their tools once they enter law firms and corporate legal roles. This strategy comes as the legal AI sector expands rapidly, fueled by advances in generative AI since the rise of ChatGPT.These startups compete with established providers like LexisNexis and Westlaw, which have long dominated legal research and are now integrating AI into their platforms. While legacy companies rely on proprietary legal databases, newer entrants build tools on large language models and focus on tasks like drafting, research, and litigation preparation. Some partnerships have even emerged between startups and traditional providers to combine strengths.Law students are already using these tools for exam preparation, memo writing, and simulating legal arguments. Schools and companies also view this exposure as a way to teach both the benefits and risks of AI, including issues like inaccurate or “hallucinated” outputs. The broader goal is to create familiarity early, making future lawyers more likely to adopt these tools in practice.Other legal tech companies, including Clio and Spellbook, are pursuing similar partnerships, expanding access across hundreds of law schools. As competition grows, early access and training are becoming key battlegrounds for shaping the next generation of legal professionals.AI startups court law students in fight for lawyer market | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

In our latest episode with the discuss the promising results of a Phase I clinical trial looking at kamuvidine 8 an inflammasome inhibitor in the treatment of geographic atrophy with Dr. Jayakrishna Ambati, Guerry Professor of Ophthalmology at the University of Virginia School of Medicine.

"We're not going to get the liberation we all crave on a soul level without risk." Andrea reflects on why, now more than ever, we must follow our hearts and refuse to let fear, or Steve Bannon, that Jabba the Hutt of American politics, live rent-free in our heads. Being brave, taking risks: that's how we win. In this special excerpt from last Monday's Gaslit Nation Salon, Andrea honors her beloved uncle, Phil Bourne. "Uncle Phil" was the founding dean of the University of Virginia School of Data Science, earned more than 100,000 citations on Google Scholar, championed the collaboration between the liberal arts and STEM as essential to the future of education, and served as the founding Editor-in-Chief of PLOS Computational Biology, where he created the "Ten Simple Rules" series. Honor Uncle Phil's memory by reaching out to your loved ones and saying what's truly in your heart. We do not have as much time here as we think. Don't let the fascists steal that time from you. Bethany McKee, founder of the Outreach Committee, a group that meets to discuss how to deal with the MAGA cultists in our lives as they awaken to their own self-destruction, will host today's Gaslit Nation Salon at 4 p.m. ET. You can find the Zoom link at Patreon.com/Gaslit. Thank you to everyone who supports the show. We could not make Gaslit Nation without you. Join us for an evening honoring the power of art and defiance at the book launch of Mrs. Orwell, Andrea's inspiring new graphic novel, illustrated by Brahm Revel. When: April 13 Where: PowerHouse Books Arena, DUMBO, Brooklyn Details here: https://powerhousearena.com/events/book-launch-mrs-orwell-by-andrea-chalupa-in-conversation-with-nomiki-konst/ Patreon Supporters: You and your guests get in free and receive a complimentary book! Just message us through Patreon to claim yours. Not a member yet? Join our community at Patreon.com/Gaslit. We couldn't make this show without you–see you there!  

Nearly two centuries after President James Monroe announced a landmark foreign-policy principle in his 1823 address to Congress, the Monroe Doctrine continues to resonate and prompt debate in U.S. strategic thinking toward Latin America. Originally articulated to warn European powers against new colonial ventures in the Western Hemisphere and to assert a sphere of influence rooted in American security interests, the Doctrine helped define the United States’ role in the hemisphere throughout the 19th and 20th centuries. Over time, it has been extended, reinterpreted, and invoked in a series of diplomatic and military contexts — from the Venezuelan boundary dispute under President Grover Cleveland to various interventions throughout Central America and the Caribbean. Recently, the Monroe Doctrine has reemerged at the center of discussion following U.S. operations in Venezuela earlier this year and more recently in Ecuador. Conversations debating whether these actions signal a return to an assertive interpretation of the Doctrine are taking place with questions about what implications this holds for the nature of U.S. power in the Americas. Featuring:Prof. John C. Harrison, James Madison Distinguished Professor of Law and Class of 1941 Professor of Law, University of Virginia School of LawProf. John C. Yoo, Emanuel Heller Professor of Law and Faculty Director, Public Law & Policy Program, University of California at Berkeley(Moderator) Prof. Jeremy Rabkin, Professor Emeritus of Law, Antonin Scalia Law School, George Mason University

On March 17, 2026, Professor John F. Duffy joined William & Mary Law School's Center for the Study of Law and Mark to present a lecture on “Property Theory and the Emergence of NIL Rights.” Professor Duffy is the Samuel H. McCoy II Professor of Law at the University of Virginia School of Law.

pWotD Episode 3246: Robert Mueller Welcome to popular Wiki of the Day, spotlighting Wikipedia's most visited pages, giving you a peek into what the world is curious about today.With 510,191 views on Sunday, 22 March 2026 our article of the day is Robert Mueller.Robert Swan Mueller III (; August 7, 1944 – March 20, 2026) was an American lawyer who served as the sixth director of the Federal Bureau of Investigation (FBI) from 2001 to 2013.A graduate of Princeton University and New York University, Mueller served as a Marine Corps officer during the Vietnam War, receiving a Bronze Star for heroism and a Purple Heart. He later attended the University of Virginia School of Law. Mueller was a registered Republican in Washington, D. C., and was appointed or reappointed to Senate-confirmed positions by presidents George H. W. Bush, Bill Clinton, George W. Bush, and Barack Obama.Mueller worked in both government and private practice. He served as an Assistant U. S. attorney, a U. S. attorney, the U. S. assistant attorney general for the Criminal Division, a homicide prosecutor in the U. S. District Court for the District of Columbia, acting U. S. deputy attorney general, a partner at the Washington D. C. law firm WilmerHale, and director of the FBI. He was the only FBI director permitted by Congress to serve more than the statutory 10‑year term limit since the death of J. Edgar Hoover in 1972, receiving a special two‑year extension.In 2017, Mueller was appointed special counsel to oversee the investigation into Russian interference in the 2016 U. S. presidential election and related matters. He submitted his report in 2019, after which the Office of the Special Counsel was closed and Mueller resigned.This recording reflects the Wikipedia text as of 03:37 UTC on Monday, 23 March 2026.For the full current version of the article, see Robert Mueller on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Mastodon at @wikioftheday@masto.ai.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm standard Amy.

Professors Alice Abrokwa, Charles Barzun '05 and Richard Schragger talk to students about their academic career paths and the steps needed to become a law school professor. All three serve on UVA Law's Academic Placement Committee. (University of Virginia School of Law, Feb. 18, 2026)

Over the next few weeks, Legal Speak will feature a series of interviews from our sister podcast, "Supreme Court Brief." In this first installment, Supreme Court Brief host Jimmy Hoover interviews University of Virginia School of Law Professor Amanda Frost. The duo discuss Frost's latest research on the original understanding of the Fourteenth Amendment's citizenship clause and how it conflicts with President Donald Trump's attempt to deny birthright citizenship to children of immigrants. With the U.S. Supreme Court expected to weigh the constitutionality of Trump's policy this term and issue a ruling by July, the conversation provides timely insights for legal listeners.   Hosts: Cedra Mayfield & Patrick Smith Special Guest Host: Jimmy Hoover Guest: Amanda Frost Producer: Charles Garnar

Jessica Lake, a senior lecturer at Melbourne Law School in Australia, discussed her latest book, “Special Damage: The Slander of Women and the Gendered History of Defamation Law.” Professor Danielle Citron, co-director of the LawTech Center, introduced Lake at the event. (University of Virginia School of Law, Feb. 10, 2026)

Podcast Description: In Part 1 of this two-part episode of Whiskey, Jazz & Leadership, host Galen Bingham sits down with the extraordinary Dr. David Wilkes, a renowned physician, researcher, and leader in academic medicine. With a career spanning over four decades, Dr. Wilkes has been at the forefront of medical education, research, and leadership, mentoring countless physicians and shaping the future of healthcare.   Dr. Wilkes shares his inspiring journey from growing up in a planned integrated community to becoming a pulmonary critical care physician, groundbreaking researcher, and former Dean of the University of Virginia School of Medicine. This episode explores his passion for mentorship, his groundbreaking discoveries in lung transplant rejection, and the importance of improvisation in leadership.   Listen in as Dr. Wilkes Reflects on: His Journey: From a childhood shaped by civil rights activism to leading in academic medicine. Mentorship and Legacy: Why opening doors for the next generation is his most important work. Groundbreaking Research: His discovery of the role of type five collagen in lung transplant rejection. Improvisation in Leadership: Why adaptability and action are essential for effective leadership. The Influence of Jazz: How the improvisational nature of jazz mirrors the challenges of leadership.   What you drinking? Galen reaches for the @remusbourbon Remus Gatsby Reserve, a 15-year straight bourbon whiskey clocking in at 104.9 proof. With hints of honey, dried fruits, and a touch of pepper, this top-shelf bourbon is the perfect match for a conversation of this caliber. Meanwhile, Dr. Wilkes enjoys Jefferson Reserve Bourbon, aged in Cabernet barrels, offering a unique and extraordinary flavor profile that reflects his refined taste and thoughtful approach to leadership.   Want more? For four dollars a month, you can become a Patreon VIP. You'll get early access to every Part Two episode. A deep archive of exclusive conversations. Insight into who's coming next. And direct access to Galen himself. Join the VIP circle today Click Here. Cheers to leadership that matters!  

Former UVA Rector George Keith Martin (College '75), counsel at McGuireWoods, speaks about Martin Luther King Jr.'s leadership as part of UVA's Community MLK Celebration. At the event, Dean Leslie Kendrick '06 presented the Gregory H. Swanson Award to Amelia Isaacs '26. Professor Kimberly Jenkins Robinson introduced Kendrick and Martin. (University of Virginia School of Law, Jan. 21, 2026)

Full Show Notes: https://bengreenfieldlife.com/lnleland/ From the science behind sunlight, circadian lighting, and EMFs to practical tips on breathwork, cold exposure, and personalized nutrition, this wide-ranging conversation is packed with actionable insights. You'll learn why optimizing your external environment—light, air, water, and even mindset—is just as vital as what you eat, plus discover how environmental factors can impact everything from immune health to sleep quality. Whether you're a health enthusiast or just curious about leveling up your wellbeing, this episode delivers a blend of cutting-edge science and real-world strategies that will inspire you to rethink your daily routine. Dr. Leland Stillman is one interesting doctor and a man after my own heart - meaning he's interested in everything from how polar bears use cold thermogenesis and hibernation to enhance longevity to how your environment drastically shapes your health no matter how hard you exercise or how perfectly you eat. He became interested in natural and integrative medicine at an early age. After majoring in environmental health at Connecticut College and earning his medical doctorate from the University of Virginia School of Medicine, Dr. Stillman completed his training in internal medicine at Maine Medical Center. Board-certified in internal medicine and specializing in integrative medicine, he has a passion for doing whatever it takes to discover the root cause of his patients' medical problems through advanced laboratory testing and then addressing those imbalances with dietary or lifestyle interventions. Dr. Stillman focuses not only on the patient but on all aspects of the environment they live in. Some of Dr. Stillman's professional interests include phototherapy (photobiomodulation), nutrition, toxicology, and the immune system. Episode Sponsors: Troscriptions: Explore Troscriptions' revolutionary buccal troche delivery system that bypasses digestion to deliver pharmaceutical-grade, physician-formulated health optimization compounds directly through your cheek mucosa for faster onset and higher bioavailability than traditional supplements. Discover a completely new way to optimize your health at troscriptions.com/BEN or enter BEN at checkout for 10% off your first order. LVLUP Health: I trust and recommend LVLUP Health for your peptide needs as they third-party test every single batch of their peptides to ensure you’re getting exactly what you pay for and the results you’re after! Head over to lvluphealth.com/BGL and use code BEN15 for a special discount on their game-changing range of products. Qualia: Support better aging with Qualia Senolytic and boost brain health with Qualia Mind—two of my favorites! Visit qualialife.com/boundless and use code BOUNDLESS for 15% off your order. Ultimate Longevity: Ready to hack your sleep and stay grounded while recovering? Head to ultimatelongevity.com/ben to get your hands on grounding mats for your mattress, pillow, blankets, and other valuable tools to help you bring down your inflammation and jumps start your healing. See omnystudio.com/listener for privacy information.

On today's episode, Lawfare Senior Editor Scott R. Anderson sits down with Lawfare Contributing Editor Professor Ashley Deeks of the University of Virginia School of Law and Professor Kristen Eichensehr of Harvard Law School to discuss their recent article entitled, "Federalism and the New National Security," recently published in the Harvard Law Review.Together, they discuss the new ways that states are engaging in national security policy (which Deeks and Eichensehr call "entrepreneurial federalism"), the costs and benefits of such practices, and strategies for how the states and the various branches of the federal government should engage with them.To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.

A recent College Board survey found the majority of high schoolers use Generative A-I tools, such as Chat GPT, for schoolwork, even though nearly half of American schools restrict its use. As educators struggle to keep pace with AI, one rural Virginia school system is embracing it. Christine Kueter explains.

In this episode of the VSBA School Board News Podcast, Executive Director Gina Patterson is joined by Ernesto Hernandez, Regional Sales Director for BuyBoard, to discuss how the national purchasing cooperative helps school divisions save time, ensure compliance, and maximize resources. Learn how BuyBoard works, what sets it apart from traditional procurement methods, and how Virginia school boards and division leaders can use cooperative purchasing to support both educational and operational needs.

OUR FAMILY MUSIC ACADEMY: Affordable and effective online weekly music lessons designed for families. https://www.voetbergmusicacademy.comUse coupon code: PODCASTVMA for 10% off each month-Stephanie Gray Connors is married and a mother to two small children, ages 2 and 4. She is an author and international speaker who has given more than 1,000 pro-life presentations over two decades across North America as well as in Scotland, England, Ireland, Austria, Latvia, Guatemala, Mexico, and Costa Rica. She has spoken at many post-secondary institutions, such as Cornell University, the University of Virginia School of Law, and the University of California, Berkeley. In 2017, Stephanie was a presenter for the series Talks at Google, lecturing at Google headquarters in California. Stephanie is author of On IVF (The Dignity Series), My Body for You: A Pro-Life Message for a Post-Roe World, On Assisted Suicide (The Dignity Series), and Love Unleashes Life: Abortion & the Art of Communicating Truth. She holds a bachelor of arts in political science from the University of British Columbia and a certification, with distinction, in health care ethics from the National Catholic Bioethics Center. Upcoming speaking event: Students for Life of America, Washington, D.C. in January Website: https://loveunleasheslife.com/

Today, we're diving into one of the most fascinating topics, near-death experiences, and one of the deeply human questions of our time: What happens when we come close to death—and why does it change people forever? Joining me is Dr. Marieta Pehlivanova, Research Assistant Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia School of Medicine, and a leading researcher at the renowned Division of Perceptual Studies. Today, we explore what near-death experiences are, what people report during them, why these moments are so transformative, and how her research is shaping new approaches to care and support for those who've experienced them. We'll also take a look at how science is evolving to better understand these experiences—and where the field is headed next. Follow Chrissy Newton: Winner of the Canadian Podcast Awards for Best Science Series. YouTube: https://www.youtube.com/channel/UCM32gjHqMnYl_MOHZetC8Eg  Instagram: https://www.instagram.com/beingchrissynewton/  X: https://twitter.com/chrissynewton?lang=en Facebook: https://www.facebook.com/BeingChrissyNewton  Chrissy Newton's Website: https://chrissynewton.com Top Canadian Science Podcast: https://podcasts.feedspot.com/canadian_science_podcasts/       

This episode features an exciting conversation with Amber N. Wiley, PhD, who has just published her new book titled 'Model Schools in the Model City: Race, Planning, and Education in the Nation's Capital' The interview covers various topics including the challenges and triumphs of writing her book during the pandemic as well as the history and architecture of black schools in Washington, DC. Amber also discusses her upbringing, the significance of black public high schools, and the efforts to get them recognized as national historic landmarks. The interview concludes with a look at Amber's future projects and her upcoming book tour events.Amber N. Wiley Ph.D. is the Wick Cary Director of the Institute for Quality Communities. An award-winning scholar, Wiley has over 20 years of experience in teaching, research and professional practice in historic preservation, architecture and community engagement. She has dedicated her career to advancing the history and narrative of design and preservation in Black communities, as well as advocating for theoretically rigorous, thoughtful and inclusive expansions of preservation policy and practice. She currently serves on the board of the Oklahoma Foundation for Excellence. Her first book, Model Schools in the Model City: Race, Planning, and Education in the Nation's Capital was released by the University of Pittsburgh Press in April 2025. Her second book, Collective Yearning: Black Women Artists from the Zimmerli Art Museum is scheduled for release by the Rutgers University Press in May 2026.Amber received her Ph.D. in American Studies from George Washington University. She also holds a Master's in Architectural History and Certificate in Historic Preservation from the University of Virginia School of Architecture, and a B.A. in Architecture from Yale University. She is a native of Oklahoma City with roots in Washington, DC, Maryland, North Carolina, and Arkansas.Learn More:Purchase Model Schools in the Model City: Race, Planning, and Education in the Nation's Capital at www.ambernwiley.com and https://dchistory.org/events/book-talk-model-schools/Watch Clips:Walter Fauntroy, Urban Renewal and The Model City Video Short: https://youtube.com/shorts/s_-AKvIGZfY?feature=share

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Steve Gruber sits down with Seena Saiedian, a panelist at the Free Iran Convention 2025 and J.D. candidate at the University of Virginia School of Law. Seena shares insights from his work advocating for freedom and democracy in Iran, his experiences as a Karsh-Dillard Scholar, editor on the Virginia Law Review, and Symposium Chair for the Federalist Society, and highlights what attendees can expect from this year's convention. The conversation explores the importance of civic engagement, international human rights, and the ongoing fight for liberty in Iran.

Relying solely on the central laboratory for urinalysis testing comes with the risk of losing patients to follow up. In this episode of Laborastories, hosted by Dr. Ian Lentnek from Siemens Healthineers, Dr. Nicholas Larkey, point-of-care (POC) medical director and assistant professor of pathology at the University of Virginia School of Medicine, discusses the advantages of POC testing for urinalysis and how to leverage it to increase workflow efficiency, generate faster results, and improve diagnostic accuracy. This is a paid advertisement for Laborastories' listeners brought to you by Siemens Healthineers. The views expressed do not necessarily represent ADLM's views, and their inclusion in this podcast is not an endorsement by Laborastories or ADLM. With special guest: Dr. Nicholas Larkey, point-of-care medical director and assistant professor of pathology at the University of Virginia School of Medicine Hosted by: Dr. Ian Lentnek, medical director, point of care diagnostics, Siemens Healthineers

In this episode of Status Check with Spivey, Mike has a conversation with Dayna Bowen Matthew, Dean of the George Washington University Law School, where she has led the law school since 2020. Prior to her time at GW, she was a Professor of Law at the University of Virginia School of Law, the University of Colorado Law School, and the University of Kentucky College of Law, and she has served as a Senior Advisor to the Office of Civil Rights of the Environmental Protection Agency (EPA). She is a graduate of Harvard University (AB), the University of Virginia School of Law (JD), and the University of Colorado (PhD).Mike and Dean Matthew discuss the increase in law school applicants this cycle (7:42 and 18:11), advice for applying during a competitive cycle (12:16), how the large firm hiring process in law school has changed into something that "bears no resemblance" to how it worked for decades (5:11), how the public interest and government hiring process has changed as well (6:27), how AI could impact legal employment in the future (24:10), why she chose the law school where she attended (2:33), what she would do differently if she were applying today (3:36), how to assess law schools' varying "personalities" (13:22), the fungibility of a JD (16:45), advice for law students (18:53), and what it's like being a law school dean in 2025 (28:53).You can read more about Dean Matthew here. We discussed two additional podcast interviews in this episode: "How Law School Hiring Has Changed (Rapidly) & How That Impacts Admissions""Emmy-Winning News Anchor Elizabeth Vargas on Overcoming Professional Setbacks and Anxiety."Note: Due to an unexpected technical issue during recording, Mike's audio quality decreases from 7:35 onward. Apologies for any difficulties this may cause, and please note that we have a full transcript of the episode linked below.You can listen and subscribe to Status Check with Spivey on ⁠⁠Apple Podcasts⁠⁠, ⁠⁠Spotify⁠⁠, and ⁠⁠YouTube⁠⁠. You can read a full transcript with timestamps here.

World Awareness Week:Jesse Rudy Jesse Rudy is Founder and CEO of Redeem International. An attorney by training, Jesse spent 12 years with International Justice Mission, leading teams in Sri Lanka, Uganda, and the Philippines, before serving on IJM's global leadership team in the United States. In February 2020, Jesse launched Redeem to protect the homes and land of the world's most vulnerable widows and orphans. Jesse graduated from John Brown University ('99) and the University of Virginia School of Law. He lives just outside of Washington, D.C., with his wife Amy and their three children.

“I'm boooored!” Sound familiar? Athena and Mims unpack why boredom isn't a problem to solve—it's a skill to practice. From resisting the quick-fix screen handoff to nudging kids toward self-directed play, they dive into how unfilled moments spark creativity, problem-solving, time management, and real conversation (yes, even about why they're “bored”). Expect candid mom-moments, basement-play nostalgia, and practical ways to leave white space in family life—without turning you into the cruise director of your house. What you'll hear:Why “I'm bored” doesn't have to become your emergency

World Awareness Week:Jesse RudyJesse Rudy is Founder and CEO of Redeem International. An attorney by training, Jesse spent 12 years with International Justice Mission, leading teams in Sri Lanka, Uganda, and the Philippines, before serving on IJM's global leadership team in the United States. In February 2020, Jesse launched Redeem to protect the homes and land of the world's most vulnerable widows and orphans. Jesse graduated from John Brown University ('99) and the University of Virginia School of Law. He lives just outside of Washington, D.C., with his wife Amy and their three children.

A leading authority on China's economy and financial system, Leland is the co-founder and CEO of China Beige Book International.Leland is a frequent commentator on media outlets such as CNBC, Bloomberg TV & Radio, CNN, BNN, BBC, and FOX Business, and he has served as a guest host of two of the financial world's top morning news shows, CNBC Squawk Box and Bloomberg Surveillance. His work is featured regularly in the Wall Street Journal, New York Times, Washington Post, TIME, New Yorker, The Atlantic, Forbes, Foreign Policy, The Hill, and South China Morning Post.Before co-founding China Beige Book in 2010, Leland was a capital markets attorney based out of New York and Hong Kong and worked on the deal team at a major investment bank. He holds a law degree from the University of Virginia School of Law, where he was Hardy C. Dillard fellow and editor-in-chief of the International Law Journal; a master's degree in Chinese History from Oxford University; a BA in European History from Washington & Lee University; and a graduate Chinese language fellowship from Tunghai University (Taiwan).Leland is an elected member of the National Committee on U.S.-China Relations and Economic Club of New York, an elected life member of the Council on Foreign Relations, a board member of the Global Interdependence Center, and a non-resident Senior Fellow at the Brent Scowcroft Center on International Security at the Atlantic Council. Learn more about your ad choices. Visit megaphone.fm/adchoices

Professors Ross E. Davies of George Mason University, Lucas A. Powe Jr. of the University of Texas and Sarah A. Seo of New York University discuss UVA Law professor G. Edward White's new book, “Robert H. Jackson: A Life in Judgment.” Professor Risa Goluboff moderated the panel and Dean Leslie Kendrick '06 introduced the event, which was sponsored by the Law School and co-sponsored by the Legal History Program. (Oct. 9, 2025, University of Virginia School of Law)

“Kindergarten skills, right? If you're a pain to be around, you can be the best clinically, but no one wants to hang out with you at 2 a.m. when that bleed comes in.”- Viknesh Kasthuri, MDIn this episode, host Marie Hamel and guest Viknesh Kasthuri, MD, a resident at the University of Virginia School of Medicine, discuss all your burning questions about the match process, including how to prepare and how to cope with the stress of the match process. Related resources:Read more about the IR Integrated Residency.Learn more about upcoming Meet and Greet opportunities.SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology. Senior Editorial Manager, Hope Racine, explains the work she does at SIR. Support the show

Philip J. Cozzolino is an Associate Professor of Research in the Division of Perceptual Studies at the University of Virginia School of Medicine. Philip received his Ph.D. in Psychology from the University of Minnesota in 2006 and spent 17 years at the University of Essex in the United Kingdom prior to joining DOPS.Philip's research explores how individuals seek meaning in life, with a particular focus on the positive psychological consequences of death awareness. Inspired by evidence from DOPS-generated research into near-death experiences, Philip is responsible for a psychological model that links healthy and honest considerations of human mortality to increased well-being, heightened desires for self-direction, and more authentic living. His work has been covered in the ‘Huffington Post', ‘Psychology Today', ‘Scientific American', ‘BBC Radio 4' and has generated research from numerous psychologists around the world.At DOPS, Philip's initial focus will be on investigating – and elucidating processes related to – reports of past-life memories from children around the world.Research Interests:Near-death experiencesChildren reporting past-life memoriesPsychological consequences of mortality awarenessOut-of-body experienceshttps://med.virginia.edu/perceptual-studies/dops-staff/philip-cozzolino-phd/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the government, sanctions and export controls are foreign policy tools. For businesses, they are legal minefields. Audi Syarief is a senior associate who helps clients navigate this high-stakes world of regulatory puzzles and enforcement actions. In this episode, Audi explains how sanctions work, the outsized role of ambiguity in his practice, and his approach to managing risk across diverse client situations. He discusses the collaborative nature of working with deal teams, solving complex sanctions puzzles that can make or break deals, and how lawyers help keep clients compliant while enforcement agencies watch closely. From panicked calls about accidental violations to negotiating licenses with government regulators, Audi works at the intersection of law and foreign policy. Audi is a graduate of the University of Virginia School of Law.This episode is hosted by Kyle McEntee.Mentioned in this episode:Learn more about Rutgers LawLearn more about Vermont LawAccess LawHub today!Learn more about Rutgers LawColorado LawLearn more about Colorado Law

Many times over Charlie Kirk's life those that opposed the idea of anyone hearing his message would threaten disruption on College Campuses where Turning Point USA was attempting to hold an event. This would give the administrators just enough cover to pull the plug under concerns for ‘disruption.' As the movement grew that became less frequent and as the “Prove Me Wrong” events welcomed opposing viewpoints it had seemingly gone the way of the dodo. Well, it came back. This time it was the Turning Point USA chapter at Western Albemarle High School that became the focal point of the threat as they scheduled Victoria Cobb, President of the Family Foundation, to visit with them on October 1. At first, the school pulled the plug citing, that's right, concerns over ‘disruption.' Not that the TPUSA meeting was going to be disruptive, no. That the ‘counter protest' would be. It's a classic. Then, just a 30 hours before her talk was scheduled to have taken place, the school reversed it's position saying in a statement, “Following discussions with the student leader, and with agreement on expectations to ensure the event is orderly, respectful, and concludes within the lunch period, the principal has determined that the Turning Point USA chapter at Western Albemarle High School may host its guest speaker during a regular lunchtime meeting,”  Victoria Cobb visits with us to talk about the grander landscape of potential return of the ‘cancel culture'. Keep Up With The Daily Signal   Sign up for our email newsletters:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.dailysignal.com/email⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠     Subscribe to our other shows:    The Tony Kinnett Cast: ⁠https://megaphone.link/THEDAILYSIGNAL2284199939⁠ The Signal Sitdown: ⁠https://megaphone.link/THEDAILYSIGNAL2026390376⁠   Problematic Women:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠https://megaphone.link/THEDAILYSIGNAL7765680741⁠   Victor Davis Hanson: ⁠https://megaphone.link/THEDAILYSIGNAL9809784327⁠     Follow The Daily Signal:    X:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://x.com/intent/user?screen_name=DailySignal⁠ Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/thedailysignal/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Facebook:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.facebook.com/TheDailySignalNews/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Truth Social:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://truthsocial.com/@DailySignal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  YouTube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠https://www.youtube.com/dailysignal?sub_confirmation=1⁠    Subscribe on your favorite podcast platform and never miss an episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

Many times over Charlie Kirk's life those who opposed the idea of anyone hearing his message would threaten disruption on college campuses where Turning Point USA was attempting to hold an event. This would give the administrators just enough cover to pull the plug under concerns for ‘disruption.' As the movement grew that became less […]

America has a problem. There's a nursing shortage. And it's not for lack of hopeful nurses. There's not enough clinical space! The Mary Morton Parsons Clinical Simulation Learning Center (CSLC) at University of Virginia School of Nursing is helping to alleviate that bottleneck with simulations. They get to experience Rob Craig as their first difficult patient in a range of simulations. And: Veterans Affairs hospitals are one of the largest medical providers in the nation. And recently, Sheila Ward introduced Virginia veterans to African diasporic dance and drumming. Later in the show: Teresa Salgado and her colleagues found that tens of thousands of Virginians from Hampton Roads to Wise County live far away from pharmacies. Researchers are calling these places “pharmacy deserts.” Salgado and her colleagues hope that their findings will support policy makers in creating incentives to establish pharmacies in underserved areas.

Amy Wax, professor of law at the University of Pennsylvania, talks to Timon about her cancellation, the state of academia, and western civilization.    Amy Wax is a tenured professor at the University of Pennsylvania Law School, where she has taught since 2001, holding the Robert Mundheim Professor of Law chair since 2007. A native of Troy, New York, she earned a B.S. summa cum laude in molecular biophysics and biochemistry from Yale in 1975, a Marshall Scholarship to Oxford, and an M.D. from Harvard Medical School in 1981, where she trained as a neurologist. She completed her J.D. from Columbia Law School in 1987, serving as an editor of the Columbia Law Review. Wax clerked for Judge Abner J. Mikva and argued 15 cases before the U.S. Supreme Court while working in the Office of the Solicitor General. She taught at the University of Virginia School of Law from 1994 to 2001. Her academic work focuses on social welfare law, family policy, and labor markets. In 2024, she was suspended from teaching for one year due to controversial statements, which she challenged in a lawsuit.   Learn more about Amy Wax's work: https://www.law.upenn.edu/faculty/awax/ https://www.thefire.org/cases/university-pennsylvania-following-controversial-commentary-amy-wax-faces-major-sanction-penn   ––––––   Follow American Reformer across Social Media: X / Twitter – https://www.twitter.com/amreformer Facebook – https://www.facebook.com/AmericanReformer/ YouTube – https://www.youtube.com/@AmericanReformer Rumble – https://rumble.com/user/AmReformer Website – https://americanreformer.org/   Promote a vigorous Christian approach to the cultural challenges of our day, by donating to The American Reformer: https://americanreformer.org/donate/   Follow Us on Twitter: Josh Abbotoy – https://twitter.com/Byzness Timon Cline – https://twitter.com/tlloydcline   The American Reformer Podcast is  hosted by Josh Abbotoy and Timon Cline, recorded remotely in the United States, and edited by Jared Cummings.   Subscribe to our Podcast, "The American Reformer" Get our RSS Feed – https://americanreformerpodcast.podbean.com/ Apple Podcasts – https://podcasts.apple.com/us/podcast/the-american-reformer-podcast/id1677193347 Spotify – https://open.spotify.com/show/1V2dH5vhfogPIv0X8ux9Gm?si=a19db9dc271c4ce5

On today's Top News in 10, we cover: Director of National Intelligence Tulsi Gabbard revokes security clearance from 37 current and former officials. New information shows CBS illegal 60 Minutes editing during the Harris campaign may have been a habit. Loudoun County Public Schools in Virginia suspends students for complaining about the opposite sex in their changing rooms. Keep Up With The Daily Signal Sign up for our email newsletters:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.dailysignal.com/email⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠     Subscribe to our other shows:  The Tony Kinnett Cast: ⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/7AFk8xjiOOBEynVg3JiN6g⁠⁠⁠⁠⁠⁠⁠  The Signal Sitdown: ⁠⁠⁠⁠⁠⁠⁠https://megaphone.link/THEDAILYSIGNAL2026390376⁠⁠⁠⁠⁠⁠⁠   Problematic Women:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://megaphone.link/THEDAILYSIGNAL7765680741⁠⁠⁠⁠⁠⁠⁠   Victor Davis Hanson: ⁠⁠⁠⁠⁠⁠⁠https://megaphone.link/THEDAILYSIGNAL9809784327⁠⁠⁠⁠⁠⁠⁠   Follow The Daily Signal:  X:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠https://x.com/intent/user?screen_name=DailySignal⁠⁠⁠⁠⁠⁠⁠ Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/thedailysignal/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Facebook:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://www.facebook.com/TheDailySignalNews/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Truth Social:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://truthsocial.com/@DailySignal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  YouTube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/dailysignal?sub_confirmation=1⁠⁠⁠⁠⁠⁠⁠    Subscribe on your favorite podcast platform and never miss an episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

On today's Top News in 10, we cover: Director of National Intelligence Tulsi Gabbard revokes security clearance from 37 current and former officials. New information shows CBS's illegal 60 Minutes editing during the Harris campaign may have been a habit. Loudoun County Public Schools in Virginia suspends students for complaining about the opposite sex in […]

Please enjoy this encore of Word Notes. The flagship product of the controversial Israeli spyware vendor, the NSO Group, use for remotely hacking mobile devices, most notably iPhones, via zero-click exploits. CyberWire Glossary link: ⁠https://thecyberwire.com/glossary/pegasus⁠ Audio reference link:⁠“Cybersecurity beyond the Headlines: A Conversation with Journalist Nicole Perlroth⁠,” Kristen Eichensehr, and Nicole Perlroth, University of Virginia School of Law, YouTube, 14 February 2022

In this episode of Status Check with Spivey, Anna Hicks-Jaco interviews Natalie Blazer, Assistant Dean for Admissions and Chief Admissions Officer at the University of Virginia School of Law, on the upcoming 2025-2026 admissions cycle, how applicants should be thinking about and taking into account relevant current events, and advice for prospective law students preparing to submit their applications. They discuss predictions for the 2025-26 cycle (1:56), rising LSAT and GPA medians (20:22, 27:45), changes they've made to their application this year (12:30), the new student loan cap (30:26), how admissions offices are considering applicants writing about politics and protest in the current political climate (4:18), how they evaluate applicants who have been unable to get a job after graduating from college (7:36), whether writing about AI is overdone (36:34), advice for the "Why UVA" essay (13:05), and much more. As a brief disclaimer, Dean Blazer speaks for herself and often for UVA Law in this episode; her opinions do not reflect those of all admissions officers.In addition to her work at UVA Law, Natalie has served as Director of J.D. Admissions at Georgetown University Law Center and was Associate Director of Admissions at Columbia Law School. She hosts the UVA Law podcast Admissible, which "offers insights into the world of law school admissions and a behind-the-scenes look at life as a law student through interviews with students, faculty, alumni and staff."We've interviewed Natalie twice for Status Check before, and though we weren't able to get to all of the questions that Redditors requested we ask, we answered many of them in these past episodes:An Insider Look at Admissions with UVA Law Dean Natalie Blazer (Reddit Q&A + Artificial Intelligence in Admissions)UVA Law Admissions Dean Natalie Blazer Dives Deep into Law School AdmissionsPlease note: At the time that we recorded this episode, we noted that August 2025 LSAT registrants were up 27% relative to August 2024 registrants but that that number would come down over the days of the test administration. Ultimately, August LSAT registrants landed at a 23.7% increase vs. last year.You can listen and subscribe to Status Check with Spivey on ⁠⁠Apple Podcasts⁠⁠, ⁠⁠Spotify⁠⁠, and ⁠⁠YouTube⁠⁠. You can read a full transcript of this episode (with timestamps) here.

In this episode, Richard Primus of the University of Michigan Law School and John Harrison of the University of Virginia School of Law join to discuss Primus's new book The Oldest Constitutional Question: Enumeration and Federal Power, which challenges the prevailing understanding of congressional power and argues that Congress is not limited to its textually enumerated powers. Their conversation traces how this fundamental disagreement has shaped key moments in American constitutional history, from the Founding Era to the New Deal, and why the debate remains unsettled today.    Resources Richard Primus, The Oldest Constitutional Question: Enumeration and Federal Power (2025)  Richard Primus, “'The Essential Characteristic': Enumerated Powers and the Bank of the United States,” Michigan Law Review (2018)  John Harrison, “Enumerated Federal Power and the Necessary and Proper Clause (reviewingThe Origins of the Necessary and Proper Clause by Gary Lawson, Geoffrey P. Miller, Robert G. Natelson, Guy I. Seidman),” The University of Chicago Law Review (2011)  McCulloch v. Maryland (1819)  Stay Connected and Learn More Questions or comments about the show? Email us at ⁠⁠⁠⁠⁠⁠⁠⁠podcast@constitutioncenter.org⁠⁠⁠⁠⁠⁠⁠⁠ Continue the conversation by following us on social media @ConstitutionCtr. ⁠⁠⁠⁠⁠⁠⁠⁠Sign up⁠⁠⁠⁠⁠⁠⁠⁠ to receive Constitution Weekly, our email roundup of constitutional news and debate. Follow, rate, and review wherever you listen. Join us for an upcoming ⁠⁠⁠⁠⁠⁠⁠⁠live program⁠⁠⁠⁠⁠⁠⁠⁠ or watch recordings on ⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠. Support our important work. ⁠⁠⁠⁠⁠⁠⁠⁠Donate

Lawfare Senior Editor Alan Rozenshtein sits down with Ashley Deeks, the Class of 1948 Professor of Scholarly Research in Law at the University of Virginia School of Law, to discuss her new book, “The Double Black Box: National Security, Artificial Intelligence, and the Struggle for Democratic Accountability.” They talk about the core metaphor of the book: the idea that the use of artificial intelligence in the national security space creates a "double black box." The first box is the traditional secrecy surrounding national security activities, and the second, inner box is the inscrutable nature of AI systems themselves, whose decision-making processes can be opaque even to their creators.They also discuss how this double black box challenges traditional checks on executive power, including from Congress, the courts, and actors within the executive branch itself. They explore some of Deeks's proposals to pierce these boxes, the ongoing debate about whether AI can be coded to be more lawful than human decision-makers, and why the international regulation of national security AI is more likely to resemble the fraught world of cyber norms than the more structured regime of nuclear arms control.Mentioned in this episode:"National Security AI and the Hurdles to International Regulation" by Ashley Deeks on Lawfare"Frictionless Government and Foreign Relations" by Kristen Eichensehr and Ashley Deeks in the Virginia Law ReviewTo receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.

This week, Scott sat down with his Lawfare colleagues Benjamin Wittes and Natalie Orpett, and University of Virginia School of Law professor Ashley Deeks, to talk through the week's big national security news, including:“Bracing for Fallout.” In a surprise move, President Trump joined Israel's military campaign against Iran over the weekend, using a specialized U.S. ordinance to hit Iranian nuclear sites that were beyond Israel's early reach. It's unclear to what extent the attack set back Iran's nuclear ambitions, and debates continue to rage whether the president's actions were wise or legal. But it did trigger an Iranian response against U.S. military bases in the Persian Gulf — action that was shortly followed by a tentative U.S.-backed ceasefire between Iran and Israel. What best explains the president's decision to join the military campaign? And what will the consequences be, both in the region and back home in the United States?“Destinations Unknown.” In a short, unexplained opinion in the matter of DHS v. DVD this past week, the Supreme Court stayed a lower court preliminary injunction that had barred the Trump administration from removing immigrants to third countries with minimal procedural protections against threats of torture and other mistreatment. But the exact ramifications of this holding are unclear, as the Justice Department has now returned to the Court asking for clarification as to whether its ruling also invalidates a later order applying the class-wide prohibition in the initial preliminary injunction to a specific group of individuals. What explains the Supreme Court's odd approach in this case? And what could its broader ramifications be for the Trump administration's immigration agenda?“‘Bove the Law.” A now-public internal Justice Department whistleblower report alleges that Principal Associate Deputy Attorney General—and current Third Circuit nominee—Emil Bove endorsed plans to disregard judicial orders that would have obstructed the removal of foreign nationals in directing the Department of Homeland Security that it did not need to return certain deportation flights already in the air after a judge directed as much from the bench. How serious a transgression has Bove committed if these allegations are true? And what impact will they have on his Third Circuit confirmation?In object lessons, forget day-of-the-week underpants (or pronghorn shirts)! Ben spurs on a need for more day-of-the-week monsters with the last weather report you'll ever need. Natalie is escaping, not just from reality but also from the heat, with her local bookstore, East City Bookshop. Scott shared the heartbreaking news that The Atlantic is stealing yet another Rational Security co-host emeritus as our beloved Quinta Jurecic begins her next crazy venture beneath the skies (Quinta, we miss you already!). And Ashley, channeling our bereavement at Quinta's departure, recommends Alone on the History Channel.To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.

This week, Scott sat down with his Lawfare colleagues Benjamin Wittes and Natalie Orpett, and University of Virginia School of Law professor Ashley Deeks, to talk through the week's big national security news, including:“Bracing for Fallout.” In a surprise move, President Trump joined Israel's military campaign against Iran over the weekend, using a specialized U.S. ordinance to hit Iranian nuclear sites that were beyond Israel's early reach. It's unclear to what extent the attack set back Iran's nuclear ambitions, and debates continue to rage whether the president's actions were wise or legal. But it did trigger an Iranian response against U.S. military bases in the Persian Gulf — action that was shortly followed by a tentative U.S.-backed ceasefire between Iran and Israel. What best explains the president's decision to join the military campaign? And what will the consequences be, both in the region and back home in the United States?“Destinations Unknown.” In a short, unexplained opinion in the matter of DHS v. DVD this past week, the Supreme Court stayed a lower court preliminary injunction that had barred the Trump administration from removing immigrants to third countries with minimal procedural protections against threats of torture and other mistreatment. But the exact ramifications of this holding are unclear, as the Justice Department has now returned to the Court asking for clarification as to whether its ruling also invalidates a later order applying the class-wide prohibition in the initial preliminary injunction to a specific group of individuals. What explains the Supreme Court's odd approach in this case? And what could its broader ramifications be for the Trump administration's immigration agenda?“‘Bove the Law.” A now-public internal Justice Department whistleblower report alleges that Principal Associate Deputy Attorney General—and current Third Circuit nominee—Emil Bove endorsed plans to disregard judicial orders that would have obstructed the removal of foreign nationals in directing the Department of Homeland Security that it did not need to return certain deportation flights already in the air after a judge directed as much from the bench. How serious a transgression has Bove committed if these allegations are true? And what impact will they have on his Third Circuit confirmation?In object lessons, forget day-of-the-week underpants (or pronghorn shirts)! Ben spurs on a need for more day-of-the-week monsters with the last weather report you'll ever need. Natalie is escaping, not just from reality but also from the heat, with her local bookstore, East City Bookshop. Scott shared the heartbreaking news that The Atlantic is stealing yet another Rational Security co-host emeritus as our beloved Quinta Jurecic begins her next crazy venture beneath the skies (Quinta, we miss you already!). And Ashley, channeling our bereavement at Quinta's departure, recommends Alone on the History Channel.To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute. Hosted on Acast. See acast.com/privacy for more information.

Gillian Metzger of Columbia Law School and Saikrishna Prakash of the University of Virginia School of Law join Jeffrey Rosen to examine the founders' vision for the presidency, review how presidential power has changed over time, and debate the constitutional questions—including the unitary executive theory—that have shaped the modern presidency. Resources Federalist No. 70, New York Packet (March 18, 1788) Myers v. United States (1926) Trump v. United States (2024) Saikrishna Prakash, The Living Presidency: An Originalist Argument Against Its Ever-Expanding Powers, (2020) Saikrishna Prakash, Imperial from the Beginning: The Constitution of the Original Executive, (2015) Gillian Metzger, “Disqualification, Immunity, and the Presidency,” Harvard Law Review, Vol. 138 (April 1, 2025) Stay Connected and Learn More Questions or comments about the show? Email us at ⁠⁠podcast@constitutioncenter.org⁠⁠ Continue the conversation by following us on social media @ConstitutionCtr. ⁠⁠Sign up⁠⁠ to receive Constitution Weekly, our email roundup of constitutional news and debate. Follow, rate, and review wherever you listen. Join us for an upcoming ⁠⁠live program⁠⁠ or watch recordings on ⁠⁠YouTube⁠⁠. Support our important work. ⁠⁠Donate